# Journey Medical Corp (DERM)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $149M  
**Price:** $6.07 (-1.78%)

> Journey Medical Corp is an esteemed biopharmaceutical company focused on the dermatological sector. Its primary function is to develop and commercialize innovative pharmaceutical products that address the unmet medical needs in dermatology. Journey Medical Corp's portfolio includes a wide range of dermatological products designed to treat various conditions, including acne, rosacea, and other skin disorders. The company's emphasis on dermatology allows it to significantly impact the healthcare industry by providing critical treatments that enhance patient care and outcomes. As a player in the biopharmaceutical market, Journey Medical Corp contributes to advancing medical research and development, particularly in skin care solutions. This focus not only enhances its importance in the healthcare sector but also emphasizes the growing need for specialized therapies in dermatology, underscoring its role in improving the quality of life for patients suffering from chronic skin conditions.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $61M | $40M | -$8M | -$11M | $-0.47 |
| 2024 | $55M | $34M | -$14M | -$15M | $-0.72 |
| 2023 | $60M | $37M | -$2M | -$4M | $-0.21 |
| 2022 | $71M | $40M | -$28M | -$30M | $-1.69 |
| 2021 | $63M | $31M | -$35M | -$44M | $-4.32 |
| 2020 | $45M | $30M | $8M | $5M | $0.49 |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $95M | $63M | $32M | $24M | $25M |
| 2024 | $80M | $60M | $20M | $20M | $25M |
| 2023 | $77M | $56M | $20M | $27M | $15M |
| 2022 | $105M | $88M | $17M | $32M | $28M |
| 2021 | $97M | $55M | $42M | $49M | — |
| 2020 | $52M | $42M | $10M | $8M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$12M | — | — |
| 2024 | -$9M | — | — |
| 2023 | $5M | — | — |
| 2022 | -$14M | — | — |
| 2021 | -$2M | — | — |
| 2020 | $5M | — | — |

Source: [CompaniesByCap](https://companiesbycap.com/company/DERM)